1037082-20-4Relevant academic research and scientific papers
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex
Zhang, Xiaojun,Glunz, Peter W.,Johnson, James A.,Jiang, Wen,Jacutin-Porte, Swanee,Ladziata, Vladimir,Zou, Yan,Phillips, Monique S.,Wurtz, Nicholas R.,Parkhurst, Brandon,Rendina, Alan R.,Harper, Timothy M.,Cheney, Daniel L.,Luettgen, Joseph M.,Wong, Pancras C.,Seiffert, Dietmar,Wexler, Ruth R.,Priestley, E. Scott
, p. 7125 - 7137 (2016/08/24)
Inhibitors of the tissue factor (TF)/factor VIIa complex (TF-FVIIa) are promising novel anticoagulants which show excellent efficacy and minimal bleeding in preclinical models. Starting with an aminoisoquinoline P1-based macrocyclic inhibitor, optimizatio
MACROCYCLIC FACTOR VIIA INHIBITORS
-
Paragraph 00162; 00163, (2014/01/08)
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.
MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
-
Page/Page column 100, (2008/12/07)
The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
